A Phase 1/2, Randomized, Controlled Open-label Trial to Evaluate the Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Healthy Children Aged 1 to 12 Years and in Their Relatives Living in Lambaréné, Gabon
Latest Information Update: 25 Apr 2023
Price :
$35 *
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary) ; Varicella zoster virus vaccine live
- Indications Ebola virus infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms EBOLAPED; LA rVSVdeltaG-ZEBOV-GP -02-PED
- 18 Apr 2023 Status changed from recruiting to completed.
- 31 Jul 2020 New trial record